4 news items
Analyst Ratings For Mirum Pharmaceuticals
MIRM
9 May 24
.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals
Analyst Ratings For Mirum Pharmaceuticals
MIRM
17 Apr 24
%.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive
Mirum Pharmaceuticals' LIVMARLI Receives Reimbursement Recommendation By Canada's CADTH For Patients With Cholestatic Pruritus In Alagille Syndrome
MIRM
2 Apr 24
that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has recommended public reimbursement
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
MIRM
2 Apr 24
) Canadian Drug Expert Committee (CDEC) has recommended public reimbursement for LIVMARLI® (maralixibat oral solution) for the treatment of cholestatic
- Prev
- 1
- Next